A Study of LY4337713 in Participants With FAP-Positive Solid Tumors

Part of paid clinical trials in Newport Beach, California.

Sponsor
Eli Lilly and Company
Study ID
NCT07213791
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • LY4337713 — DRUG
    Administered IV.

Study Details

This is a study of LY4337713 in participants with certain types of cancer that is advanced or has spread. Participants must have cancer with high levels of a protein called fibroblast activation protein (FAP). The purpose of this study is to evaluate safety, side effects, and efficacy of LY4337713. In addition, this study will evaluate how much LY4337713 gets into the bloodstream, how it is broken down, and how long it takes the body to get rid of it. For each participant, the study will last about 5 years.

Key Dates

Start date
Oct 22, 2025
Status verified
Jun 2026
Primary completion
Jul 31, 2028
Completion
Mar 31, 2033

Study Design

Enrollment
241 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT

Arms

  • Experimental: LY4337713 (Cohort A1)
    Escalating doses of LY4337713 administered intravenously (IV).
  • Experimental: LY4337713 (Cohort A2)
    Two or more dose regimens of LY4337713 (evaluated during dose escalation) administered IV.
  • Experimental: Experimental: LY4337713 (Cohort B)
    Tumor specific cohort will receive LY4337713 administered IV.
  • Experimental: Experimental LY4337713 (Cohort C)
    Tumor specific cohort will receive LY4337713 administered IV.
  • Experimental: Experimental: LY4337713 (Cohort D)
    Tumor specific cohort will receive LY4337713 administered IV.
  • Experimental: LY4337713 (Cohort E)
    Tumor specific cohort will receive LY4337713 administered IV.

Primary Outcome Measure

Phase 1a: Percentage of Participants with Dose Limited Toxicity (DLT) Toxicities [ Time Frame: Cycle 1 (28 days) ]

Central Contacts

  • Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
    1-317-615-4559
    [email protected]
  • Physicians interested in becoming principal investigators please contact
    [email protected]

Locations (20)

FacilityCityStateZIPSite coordinators
Hoag Memorial Hospital PresbyterianNewport BeachCalifornia92663-
Stanford University Medical CenterStanfordCalifornia94305-
Biogenix Molecular, LLCMiamiFlorida33165-
MoffittTampaFlorida33612-
Indiana University (IU) School of MedicineIndianapolisIndiana46202-
United TheranosticsGlen BurnieMaryland21061-
Beth Israel Deaconess Medical CenterBostonMassachusetts02215-
Massachusetts General HospitalBostonMassachusetts02114-
Barbara Ann Karmanos Cancer InstituteDetroitMichigan48201-
BAMF Health Inc.Grand RapidsMichigan49503-
Mayo Clinic - RochesterRochesterMinnesota55905-
Washington University School of Medicine in St. LouisSt LouisMissouri63110-
David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer CenterNew YorkNew York10065-
New York University (NYU) Clinical Cancer CenterNew YorkNew York10016-
Duke University Medical CenterDurhamNorth Carolina27710-
Fox Chase Cancer CenterPhiladelphiaPennsylvania19111-
University of PennsylvaniaPhiladelphiaPennsylvania19104-
Texas Oncology - DFW (Sammons CC)DallasTexas75246-
Baylor College of MedicineHoustonTexas77030-
University of Wisconsin - Carbone Cancer CenterMadisonWisconsin53792-

Find similar trials in Newport Beach, CA

By condition
Breast cancerColorectal cancerOvarian cancer
By specialty
OncologyBreast oncologyWomen's healthGI oncologyGynecologic oncology
By research site
Hoag Memorial Hospital Presbyterian· Newport Beach, CAStanford University Medical Center· Stanford, CABiogenix Molecular, LLC· Miami, FLMoffitt· Tampa, FLIndiana University (IU) School of Medicine· Indianapolis, INUnited Theranostics· Glen Burnie, MD

Related Studies